AndrewSChiMD

Neurology • New York, NY

Neurooncology

Director, Neuro-Oncology Program, Laura and Isaac Perlmutter Cancer Center Co-Director, Brain Tumor Center, NYU Langone Medical Center

Join to view full profile

Dr. Chi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chi's full profile

Already have an account?

Office
240 E 38th St
Fl 19
New York, NY 10016
Phone+1 646-501-4802

Fax+1 646-754-9696

Education & Training

Dana-Farber Cancer InstituteFellowship, Neuro-Oncology, 2006 - 2008
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolChief Residency, Neurology, 2005 - 2006
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2003 - 2005
Massachusetts General HospitalInternship, Internal Medicine, 2002 - 2003
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2002

Certifications & Licensure

NY State Medical License 2015 - 2019
MA State Medical License 2006 - 2017

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Start of enrollment: 2015 Jun 01
Completed
Phase 1
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Start of enrollment: 2014 Mar 12
Completed
Phase 2
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Start of enrollment: 2015 Aug 17
Active, not recruiting
Phase 2
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Start of enrollment: 2017 Mar 17
Completed
Phase 2
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma Start of enrollment: 2017 Oct 31
Active, not recruiting
Phase 2
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Start of enrollment: 2018 Feb 07
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

28 citations
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Varun V. Prabhu, Amriti R. Lulla, Neel Madhukar, Marie D. Ralff, Dan Zhao
Plos One. 2017-08-02
111 citations
A Phase 2 Study of the First Imipridone ONC201, a Selective DRD2 Antagonist for Oncology, Administered Every Three Weeks in Recurrent Glioblastoma
Isabel Arrillaga-Romany, Andrew S. Chi, Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen
Oncotarget. 2017-05-12
795 citations
Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains
Manching Ku, Richard Koche, Esther Rheinbay, Eric M. Mendenhall, Mitsuhiro Endoh
Plos Genetics. 2008-10-31

Journal Articles

Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from the Cancer Genome Atlas
D Zagzag, M Snuderl, A S Chi, American Journal of Neuroradiology

Lectures

Integrated clinical experience with ONC201 in H3 K27M glioma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Evolving Biomarkers for Outcome: Strengths and Pitfalls
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018